Individualized Treatment for Immune Thrombocytopenia: Predicting Bleeding Risk

Cindy E Neunert

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.

Original languageEnglish (US)
JournalSeminars in Hematology
Volume50
Issue numberSUPPL.1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Idiopathic Thrombocytopenic Purpura
Hemorrhage
Platelet Count
Therapeutics
Blood Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Individualized Treatment for Immune Thrombocytopenia : Predicting Bleeding Risk. / Neunert, Cindy E.

In: Seminars in Hematology, Vol. 50, No. SUPPL.1, 01.01.2013.

Research output: Contribution to journalArticle

@article{fab55c6c250944fdb8d01a4d47deff2b,
title = "Individualized Treatment for Immune Thrombocytopenia: Predicting Bleeding Risk",
abstract = "Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.",
author = "Neunert, {Cindy E}",
year = "2013",
month = "1",
day = "1",
doi = "10.1053/j.seminhematol.2013.03.009",
language = "English (US)",
volume = "50",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "SUPPL.1",

}

TY - JOUR

T1 - Individualized Treatment for Immune Thrombocytopenia

T2 - Predicting Bleeding Risk

AU - Neunert, Cindy E

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.

AB - Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.

UR - http://www.scopus.com/inward/record.url?scp=84877677053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877677053&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2013.03.009

DO - 10.1053/j.seminhematol.2013.03.009

M3 - Article

C2 - 23664518

AN - SCOPUS:84877677053

VL - 50

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - SUPPL.1

ER -